Litigation Details for Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Docket		Date Filed	2016-12-05
Court	District Court, D. Delaware	Date Terminated	2019-05-08
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED
Patents	7,709,517; 8,183,274; 9,126,941
Attorneys	Lance A. Soderstrom
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-05				External link to document
2016-12-04	104		STIPULATION Regarding Infringement of U.S. Patent Nos. 7,709,517 and 8,183,274 by Astellas Pharma Inc., Astellas…December 2016 8 May 2019 1:16-cv-01120 830 Patent None District Court, D. Delaware	External link to document
2016-12-04	105		Stipulation Regarding Infringement of U.S. Patent Nos. 7,709,517 and 8,183,274 filed by Medivation, Inc.,…December 2016 8 May 2019 1:16-cv-01120 830 Patent None District Court, D. Delaware	External link to document
2016-12-04	154		Gelmann, M.D. on the Invalidity of U.S. Patent Nos. 7,709,517 and 8,183,274; and (2) Opening Expert Report…Brian S.J. Blagg on the Invalidity of U.S. Patent Nos. 7,709,517 and 8,183,274 filed by Cadila Healthcare…December 2016 8 May 2019 1:16-cv-01120 830 Patent None District Court, D. Delaware	External link to document
2016-12-04	163	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,709,517 B2; 8,183,274 B2; 9,126,941…December 2016 8 May 2019 1:16-cv-01120 830 Patent None District Court, D. Delaware	External link to document

Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc., 1:16-cv-01120: Litigation Summary and Patent Analysis

Last updated: August 26, 2026

Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:16-cv-01120, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Zydus’ abbreviated new drug application for a generic version of Myrbetriq, whose active ingredient is mirabegron. Astellas asserted patents covering the mirabegron drug product and formulation. The case was resolved before a public merits decision determining patent validity or infringement. The public record indicates that the dispute ended through settlement and dismissal rather than a trial judgment. [1]

What drug and ANDA were at issue in Astellas v. Zydus?

The case involved Myrbetriq extended-release tablets, an oral beta-3 adrenergic receptor agonist approved for overactive bladder and related urinary urgency, frequency, and urge incontinence indications.

Item	Details
Brand	Myrbetriq
Active ingredient	Mirabegron
Dosage form	Extended-release tablet
Reference applicant	Astellas Pharma Inc.
Generic applicant	Zydus Pharmaceuticals (USA) Inc.
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-01120
Filing period	2016
Case type	Paragraph IV patent litigation
Disposition	Settlement and dismissal, without a public merits judgment

Myrbetriq was approved by the FDA on June 28, 2012. The drug was approved for overactive bladder and later received an additional approval for neurogenic detrusor overactivity in pediatric patients. [2]

What patents protected Myrbetriq in the Zydus litigation?

Astellas’ case centered on patents listed for mirabegron drug products, including patents directed to the composition and pharmaceutical formulation of mirabegron.

The principal Myrbetriq patent family included the following U.S. patents:

U.S. patent	General subject matter	Listed expiration position
8,410,167	Mirabegron pharmaceutical composition	December 2028, before any applicable pediatric extension
8,835,474	Mirabegron pharmaceutical composition and formulation	December 2028, before any applicable pediatric extension
9,353,175	Mirabegron pharmaceutical composition and formulation	December 2028, before any applicable pediatric extension
Later continuation patents	Additional product, formulation, or use claims	Potentially later dates depending on claim scope and listing

Patent numbers and listing status should be evaluated against the relevant FDA Orange Book edition because patent listings can change during prosecution, maintenance, delisting, or regulatory updates. The core commercial patent position for the original Myrbetriq product extended materially beyond the drug’s five-year new chemical entity exclusivity period. [3]

The asserted estate was important because it addressed the marketed extended-release product rather than merely the existence of mirabegron as a chemical compound. Formulation protection can delay generic substitution when an ANDA applicant seeks approval for the same extended-release dosage form.

What was Astellas’ infringement theory?

Astellas filed the action after receiving notice of Zydus’ Paragraph IV certification. Zydus’ certification represented that the relevant Orange Book patents were invalid, unenforceable, or would not be infringed by the proposed ANDA product.

The litigation therefore followed the standard statutory framework:

1. Zydus submitted an ANDA seeking approval of generic mirabegron extended-release tablets.
2. Zydus provided Paragraph IV notice to Astellas.
3. Astellas filed an infringement action within the statutory period.
4. The filing triggered the Hatch-Waxman 30-month stay of final FDA approval, subject to statutory exceptions.
5. The parties resolved the case without a publicly reported trial judgment.

Astellas’ claims would have focused on whether Zydus’ proposed product met the limitations of the asserted mirabegron composition and formulation claims. Zydus’ defenses likely included non-infringement, invalidity, and potentially unenforceability. The public disposition did not establish a binding judicial ruling on those defenses.

Was this a Paragraph IV challenge?

Yes. The case was a Paragraph IV ANDA dispute.

A Paragraph IV certification is a generic applicant’s position that an Orange Book-listed patent is invalid, unenforceable, or not infringed. It permits the applicant to seek FDA approval before the listed patent expires, but it also exposes the applicant to patent litigation.

The filing of Astellas’ complaint created the statutory 30-month approval stay. The stay is separate from patent expiration and does not itself determine whether a generic may ultimately launch. A settlement can establish an agreed launch date or other conditions that control commercial entry.

What was the litigation outcome?

The case did not produce a public district court judgment resolving patent validity or infringement. The docket reflects settlement-based termination and dismissal.

Issue	Public outcome
Patent validity	No public merits adjudication
Patent infringement	No public merits adjudication
Injunction	No litigated permanent injunction
Settlement	Yes
Settlement terms	Not publicly disclosed in full
FDA approval impact	Controlled by the settlement, regulatory status, and patent listings
Commercial launch date	Not established by a public merits opinion

The absence of a merits decision limits the precedential value of the case. It does not mean the patents were held valid or infringed. It means the parties avoided a final judicial determination.

When could Zydus launch generic mirabegron?

The precise Zydus launch date was governed by the settlement agreement and the remaining regulatory and patent constraints. A settlement can permit an authorized or licensed generic launch before patent expiration, provide a defined generic entry date, or impose conditions tied to patent validity, regulatory approval, or another generic applicant’s entry.

The public docket does not provide a merits-based date at which a court declared Zydus free to launch. The commercially relevant dates were:

Milestone	Date or status
Myrbetriq FDA approval	June 28, 2012
Five-year NCE exclusivity	Expired in 2017
Astellas-Zydus litigation	Filed in 2016
30-month stay	Triggered by the infringement action, subject to statutory rules
Settlement	Case resolved without a public trial judgment
Core listed patent horizon	Approximately December 2028, before any pediatric extension
Generic entry	Dependent on settlement terms, FDA approval, and remaining patent barriers

The key commercial point is that regulatory exclusivity expired well before the principal patent horizon. FDA approval could therefore proceed only if the statutory stay expired, the patents expired, the ANDA applicant prevailed, or the parties’ settlement permitted earlier entry.

What was the Orange Book status of Myrbetriq?

Myrbetriq was listed in the FDA Orange Book with patents associated with the approved mirabegron extended-release product. The listings created the basis for Paragraph IV certifications and the resulting patent litigation.

Orange Book-listed patents can cover:

• The active pharmaceutical ingredient or drug composition.
• The extended-release formulation.
• The approved dosage form.
• Approved methods of use.
• Pediatric or indication-specific uses, where applicable.

The Orange Book does not determine patent validity. It identifies patents submitted by the NDA holder or patent owner that are associated with the approved drug. A listed patent can be challenged in ANDA litigation and can later be invalidated, narrowed, delisted, or allowed to expire. [3]

Did the case involve formulation patents?

Yes. Formulation protection was central to the commercial patent position for Myrbetriq.

Mirabegron is marketed as an extended-release tablet. Formulation patents can protect excipient combinations, release characteristics, tablet structure, manufacturing parameters, or pharmaceutical composition limitations. Their value depends on whether the generic product uses the same or an equivalent formulation and whether the asserted claims survive invalidity challenges.

For an ANDA applicant, formulation claims create several potential barriers:

• The product may need to be designed around the claim limitations.
• The applicant may need to provide a detailed Paragraph IV non-infringement position.
• A formulation redesign may affect bioequivalence or dissolution testing.
• A court may construe formulation terms broadly enough to capture the proposed generic product.

The case did not produce a public claim-construction or trial opinion that would establish how the District of Delaware interpreted the asserted Myrbetriq claims.

Did the case involve method-of-use patents?

The central dispute was associated with the Myrbetriq product and formulation patent estate. Method-of-use patents may also appear in the broader Orange Book and regulatory landscape for mirabegron, particularly after additional indications were approved.

A generic applicant can use a section viii statement to carve out a patented method of use from its labeling when the FDA permits the carve-out. A product or formulation patent presents a different problem because a labeling carve-out generally does not remove infringement risk from the physical composition or dosage form.

For this reason, product and formulation patents usually create a more direct barrier to a full-label or same-dosage-form generic than a use patent that can be omitted from labeling.

How strong was Astellas’ patent estate?

Astellas’ estate was commercially meaningful but not unlimited.

Strengths

• The patents covered the marketed extended-release product rather than only a clinical indication.
• The principal patent horizon extended approximately 11 years beyond FDA approval.
• The patents created a statutory 30-month stay after the Paragraph IV litigation was filed.
• Formulation claims can be difficult to avoid while maintaining the same release profile and bioequivalence.
• Settlement avoided an adverse merits judgment that could have accelerated generic entry.

Limitations

• The five-year NCE exclusivity period had already expired when the litigation was filed.
• Patent validity and enforceability remained contestable because the court did not issue a merits ruling.
• Continuation and formulation patents can face written-description, enablement, obviousness, anticipation, and claim-construction challenges.
• Settlement prevented the development of a public opinion confirming the estate’s litigation strength.
• A competing ANDA applicant could create separate entry pressure even after the Zydus case ended.

The estate was therefore stronger as an exclusivity platform than as a publicly adjudicated precedent. Its practical value derived from listed patents, litigation timing, formulation coverage, and settlement leverage.

Which companies could challenge Myrbetriq exclusivity?

Myrbetriq was exposed to conventional generic competition rather than biosimilar competition. Mirabegron is a small-molecule drug, not a biologic, so the Public Health Service Act biosimilar pathway does not apply.

Potential challengers included ANDA applicants that sought approval for:

• Mirabegron extended-release tablets.
• The same strengths as the reference product.
• A therapeutically equivalent product under an ANDA.
• A product with Paragraph IV certifications against listed patents.

Zydus was one of the early identified challengers. Other generic applicants could file separate cases, join coordinated proceedings, or rely on patent expiration and settlement-based entry arrangements.

What generic entry risks existed for Astellas?

The primary generic entry risks were:

1. Paragraph IV invalidity risk. A court could have invalidated one or more asserted patents.
2. Non-infringement risk. Zydus could have obtained approval if its formulation avoided the asserted claims.
3. Settlement-driven entry. Astellas could authorize or permit entry before the nominal patent expiration date.
4. Later ANDA challenges. A separate applicant could litigate different patents or rely on a different product design.
5. Regulatory substitution. Once an FDA-approved therapeutically equivalent generic entered, pharmacy substitution could rapidly reduce branded volume.
6. Pediatric-extension timing. Any applicable pediatric exclusivity could extend the effective barrier beyond the listed patent expiration.

The settlement reduced the immediate litigation risk posed by Zydus but did not eliminate broader generic erosion risk after the settlement-permitted date or patent expiry.

How did this case compare with biosimilar litigation?

This was a small-molecule Hatch-Waxman case, not a biosimilar “patent dance” proceeding.

Issue	Myrbetriq-Zydus case	Biosimilar litigation
Product type	Small molecule	Biologic
Approval pathway	ANDA	351(k) BLA
Core challenge	Paragraph IV certification	Biologics patent-exchange procedures
FDA exclusivity	NCE and pediatric exclusivity concepts	Biologic reference-product exclusivity
Substitution	Therapeutic-equivalence framework	Interchangeability framework
Patent focus	Composition and formulation	Manufacturing, formulation, treatment, and biologic-process claims

The absence of biosimilar risk is commercially relevant. Generic mirabegron entrants can generally compete through ordinary ANDA substitution once approved and legally eligible for launch.

What is the commercial significance of the litigation?

Myrbetriq was a branded, chronic-use product in a large prescription market. Generic entry risk had direct implications for Astellas’ revenue base, payer contracting, formulary position, and lifecycle-management strategy.

The litigation protected several commercial objectives:

• Preserving branded market share during the principal patent term.
• Maintaining leverage over generic applicants.
• Avoiding a public invalidity judgment.
• Preserving flexibility to negotiate an entry date.
• Protecting the extended-release product against formulation-based competition.

Because the case ended without a merits ruling, the most important business information is the negotiated entry framework rather than judicial precedent. The public docket supports the conclusion that the parties reached a settlement, but it does not provide a public judicial finding that the asserted patents were valid, infringed, or enforceable.

Key Takeaways

• Astellas v. Zydus, 1:16-cv-01120, was a District of Delaware Paragraph IV case involving generic mirabegron extended-release tablets.
• The reference product was Myrbetriq.
• The dispute centered on Astellas’ product and formulation patent estate.
• Myrbetriq’s five-year NCE exclusivity expired in 2017, while core patent protection extended approximately to December 2028 before any applicable pediatric extension.
• The case ended through settlement and dismissal, without a public merits ruling.
• No public opinion established whether Zydus’ proposed product infringed or whether the asserted patents were valid.
• Generic risk was conventional ANDA risk, not biosimilar risk.
• The settlement’s practical effect was to establish the commercial framework for Zydus’ potential entry while preserving Astellas’ avoidance of a trial judgment.

FAQs

Was Astellas v. Zydus a case about Xtandi?

No. The case identified by docket number 1:16-cv-01120 concerned Myrbetriq, the mirabegron extended-release product.

Did Zydus win the patent case?

No public merits judgment awarded victory to either party. The case was resolved through settlement and dismissal.

Did the court invalidate Astellas’ Myrbetriq patents?

No. The docket did not produce a public decision invalidating the asserted patents.

Could Zydus launch before the December 2028 patent date?

Potentially, if the settlement permitted an earlier launch and the FDA approved the ANDA. The public case disposition does not establish the full settlement terms.

Are mirabegron generics biosimilars?

No. Mirabegron is a small-molecule drug. Generic mirabegron products proceed through the ANDA pathway, not the biosimilar pathway.

References

1. U.S. District Court for the District of Delaware. (2016). Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:16-cv-01120. PACER docket records.
2. U.S. Food and Drug Administration. (2012). Myrbetriq (mirabegron) prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,410,167; 8,835,474; and 9,353,175.